Smith+Nephew Posts Strong 2025 Results, Completes Transformation and Sets 2026 Growth Targets
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Smith & Nephew Snats ( (SNN) ) has issued an update.
Smith+Nephew reported a strong finish to 2025, with fourth-quarter revenue rising to $1.70 billion and full-year revenue up 6.1% to $6.16 billion for the year ended 31 December 2025, alongside a 20.7% increase in operating profit and a 52.5% jump in free cash flow. Management highlighted that newer products drove broad-based growth above 5% across all three business units, while Orthopaedics posted its strongest quarterly revenue growth in more than two years.
The company announced on 2 March 2026 that it has completed its 12-Point Plan transformation, delivering margin expansion, sharply higher cash generation and improved adjusted ROIC despite portfolio rationalisation headwinds, and has launched a new RISE strategy with ambitious 2028 financial targets. Smith+Nephew also completed the acquisition of Integrity Orthopaedics to support its Sports Medicine ambitions and finished a $500 million share buyback in 2025, setting 2026 targets for faster underlying revenue growth around 6%, trading profit of about $1.3 billion including acquisition effects, strong free cash flow and further ROIC improvement, signalling confidence in accelerating growth and returns for shareholders and other stakeholders.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company listed in London and New York that operates across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It focuses on products such as joint replacement implants, sports medicine devices and wound care solutions, with an ambition to expand its leadership in healthcare innovation and become a global leader in Sports Medicine.
Average Trading Volume: 784,554
Technical Sentiment Signal: Buy
Current Market Cap: $15.66B
Learn more about SNN stock on TipRanks’ Stock Analysis page.
